Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
JERSEY, Channel Islands , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological
View HTML
Toggle Summary Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results
Molecular Disease Screening Microarray Feasibility Study Completed Initial Serological Disease Screening FDA 510(k) Submission Accepted Commencement of EU Expanded Immunohematology Field Trial Activities Continued Strong Top Line Growth in the Quarter and Year to Date JERSEY, Channel Islands , Jan.
View HTML
Toggle Summary Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020.
View HTML
Toggle Summary Quotient Limited Provides an Update on Recent Milestone Achievements for its MosaiQ Multimodality Multiplexing Diagnostic Platform
Initial Serological Disease Screening FDA 510k Submission Received Commencement of EU Extended Immunohematology Field Trial Activities JERSEY, Channel Islands , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in
View HTML
Toggle Summary Quotient Announces Appointment of New Chief Financial Officer Peter Buhler and Chief Operating Officer Ed Farrell
Chris Lindop to Remain as Executive Vice President Reporting to Franz Walt CEO              JERSEY, Channel Islands , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial
View HTML
Toggle Summary Quotient Limited Reports Concordance Data from MDS Concept Study
JERSEY, Channel Islands , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported positive concordance data for its MosaiQ™ Multiplex Molecular Disease Screening (MDS) Microarray
View HTML
Toggle Summary Quotient Limited to Participate in the Jefferies 2019 London Healthcare Conference
JERSEY, Channel Islands, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer, Franz Walt , the Company’s President of R&D and Manufacturing, Ed Farrell , and the Company’s Chief
View HTML
Toggle Summary Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 13,800,000 ordinary shares at a price to the public of $7.00 per
View HTML
Toggle Summary Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per
View HTML
Toggle Summary Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the
View HTML